Pharmacogenomics: Promises and Problems

So far, pharmacogenomics, the study of the effects of an individual's genetic makeup on their response to drugs, has not produced the hoped-for revolution in the pharmaceutical industry, due primarily to lagging approvals and the high cost of molecular testing. Nevertheless, the promise of personalized medicine is very real, and several exciting products have received FDA approval.

Pharmaceutical researchers took great interest in the Human Genome Project in the hopes that mapping the human genome would allow them to develop drugs and diagnostic tests tailored to the metabolic idiosyncrasies of individual patients, ushering in an era of "personalized medicine." But so far, pharmacogenomics, the study of the effects of an individual’s genetic makeup on his or her response to drugs, has not produced the hoped-for revolution in the pharmaceutical industry, for two primary reasons: roadblocks in obtaining approval and the very high cost of molecular testing. In general, reimbursement has lagged behind technological developments, but these problems are nothing new, having plagued the field of molecular diagnostics for years. Nevertheless, the promise of pharmacogenomics is very real. Already, the FDA has approved at least one DNA microchip array that can test for variations in enzymes that metabolize the breast cancer drug tamoxifen and will allow doctors to adjust doses and treatment regimens accordingly, Paul R. Billings, MD, PhD, said in a session at the annual meeting of the American Society for Clinical Pathology in October.

Genetic variations govern an individual’s ability to metabolize drugs in four basic ways, explained Dr. Billings, Vice President of Biotechnology and Healthcare Strategy and Senior Geneticist, Laboratory Corp. of America Holdings (Burlington, NC). If the target genes are completely functional, the drug will metabolize normally and a complete therapeutic response with no or minimal adverse effects will be experienced. Reduced or partially functional genes result in intermediate metabolism, with a diminished therapeutic effect and possible mild side effects. If the genes do not function at all, the patient will be unable to metabolize the drug. Under this scenario, not only will patients derive little or no therapeutic benefit from the drug, they could experience serious adverse effects due to the buildup of toxic levels of the drug in the body

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

How Structured Patient Engagement Gives Medtech Companies A Competitive Edge

 

Communication with patients has become a particularly crucial factor for investors, payers, and other healthcare decision-makers in a hostile market environment.